Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Infectious Diseases
Published in: BMC Infectious Diseases 1/2018

Open Access 01-12-2018 | Research article

Prevalence and genotype distribution of human papillomavirus infection among women in northeastern Guangdong Province of China

Authors: Pingsen Zhao, Sudong Liu, Zhixiong Zhong, Jingyuan Hou, Lifang Lin, Ruiqiang Weng, Luxian Su, Nanxiang Lei, Tao Hou, Haikun Yang

Published in: BMC Infectious Diseases | Issue 1/2018

Login to get access

Abstract

Background

Human papillomavirus (HPV) DNA testing is an important method in cervical cancer screening. However, the studies on prevalence and genotype distribution of HPV among women in northeastern Guangdong Province of China are very limited.

Methods

A total of 28,730 women attending the Department of Gynecology of Meizhou People’s Hospital (Huangtang Hospital), Meizhou Hospital Affiliated to Sun Yat-sen University between January 1st, 2013 and June 1st, 2015 were enrolled in this study. HPV type-specific distribution was tested using flow-through hybridization and gene chip.

Results

The overall prevalence of HPV infection was 19.81%, among which 79.09% were infected with high-risk HPV subtypes in the subjects. The 5 most predominant genotypes were HPV16, 52, 58, 18 and 81. Most HPV infections were observed in women aged 41–50 and women aged 30–59 accounted for a proportion of over 80%.

Conclusions

Our findings suggested a high burden of HPV infection among women in northeastern Guangdong Province of China. We identified the top 5 HPV genotypes as well as the age-specific distribution of HPV infections in this area.
Literature
1.
Spence T, Bruce J, Yip KW, Liu FF. HPV associated head and neck Cancer. Cancers (Basel). 2016;8:75.
2.
Cancer Genome Atlas N. Comprehensive genomic characterization of head and neck squamous cell carcinomas. Nature. 2015;517(7536):576–82.CrossRef
3.
Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69–90.CrossRefPubMed
4.
Wang R, Guo XL, Wisman GB, Schuuring E, Wang WF, Zeng ZY, Zhu H, Wu SW. Nationwide prevalence of human papillomavirus infection and viral genotype distribution in 37 cities in China. BMC Infect Dis. 2015;15:257.CrossRefPubMedPubMedCentral
5.
Wang Y, Wang S, Shen J, Peng Y, Chen L, Mai R, Zhang G. Genotype distribution of human papillomavirus among women with cervical cytological abnormalities or invasive squamous cell carcinoma in a high-incidence area of esophageal carcinoma in China. Biomed Res Int. 2016;2016:1256384.PubMedPubMedCentral
6.
Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127(12):2893–917.CrossRefPubMed
7.
8.
Syrjanen K, Syrjanen S. Epidemiology of human papilloma virus infections and genital neoplasia. Scand J Infect Dis Suppl. 1990;69:7–17.PubMed
9.
Weaver B, Shew M, Qadadri B, Tu W, Tong Y, Denski C, Fortenberry JD, Ermel A, Brown D. Low-level persistence of human papillomavirus 16 DNA in a cohort of closely followed adolescent women. J Med Virol. 2011;83(8):1362–9.CrossRefPubMed
10.
de Sanjose S, Diaz M, Castellsague X, Clifford G, Bruni L, Munoz N, Bosch FX. Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: a meta-analysis. Lancet Infect Dis. 2007;7(7):453–9.CrossRefPubMed
11.
Krul EJ, Van De Vijver MJ, Schuuring E, Van Kanten RW, Peters AA, Fleuren GJ. Human papillomavirus in malignant cervical lesions in Surinam, a high-risk country, compared to the Netherlands, a low-risk country. Int J Gynecol Cancer. 1999;9(3):206–11.CrossRefPubMed
12.
Forman D, de Martel C, Lacey CJ, Soerjomataram I, Lortet-Tieulent J, Bruni L, Vignat J, Ferlay J, Bray F, Plummer M, et al. Global burden of human papillomavirus and related diseases. Vaccine. 2012;30(Suppl 5):F12–23.CrossRefPubMed
13.
Spence AR, Goggin P, Franco EL. Process of care failures in invasive cervical cancer: systematic review and meta-analysis. Prev Med. 2007;45(2–3):93–106.CrossRefPubMed
14.
Poljak M, Kocjan BJ, Ostrbenk A, Seme K. Commercially available molecular tests for human papillomaviruses (HPV): 2015 update. J Clin Virol. 2016;76(Suppl 1):S3–S13.CrossRefPubMed
15.
Arbyn M, Tommasino M, Depuydt C, Dillner J. Are 20 human papillomavirus types causing cervical cancer? J Pathol. 2014;234(4):431–5.CrossRefPubMed
16.
Halec G, Alemany L, Lloveras B, Schmitt M, Alejo M, Bosch FX, Tous S, Klaustermeier JE, Guimera N, Grabe N, et al. Pathogenic role of the eight probably/possibly carcinogenic HPV types 26, 53, 66, 67, 68, 70, 73 and 82 in cervical cancer. J Pathol. 2014;234(4):441–51.CrossRefPubMed
17.
Munoz N, Bosch FX, de Sanjose S, Herrero R, Castellsague X, Shah KV, Snijders PJ, Meijer CJ, International Agency for Research on Cancer multicenter cervical Cancer study G. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med. 2003;348(6):518–27.CrossRefPubMed
18.
Cogliano V, Baan R, Straif K, Grosse Y, Secretan B, El Ghissassi F, Cancer WHOIAfRo. Carcinogenicity of human papillomaviruses. Lancet Oncol. 2005;6(4):204.CrossRefPubMed
19.
Palefsky JM, Giuliano AR, Goldstone S, Moreira ED Jr, Aranda C, Jessen H, Hillman R, Ferris D, Coutlee F, Stoler MH, et al. HPV vaccine against anal HPV infection and anal intraepithelial neoplasia. N Engl J Med. 2011;365(17):1576–85.CrossRefPubMed
20.
Patel H, Jeve YB, Sherman SM, Moss EL. Knowledge of human papillomavirus and the human papillomavirus vaccine in European adolescents: a systematic review. Sex Transm Infect. 2016;92(6):474–9.CrossRefPubMed
21.
22.
de Sanjose S, Serrano B, Castellsague X, Brotons M, Munoz J, Bruni L, Bosch FX. Human papillomavirus (HPV) and related cancers in the Global Alliance for Vaccines and Immunization (GAVI) countries. A WHO/ICO HPV Information Centre Report. Vaccine. 2012;30(Suppl 4):D1–83.PubMed
23.
Priebe AM. 2012 cervical cancer screening guidelines and the future role of HPV testing. Clin Obstet Gynecol. 2013;56(1):44–50.CrossRefPubMed
24.
Smith M, Lew JB, Simms K, Canfell K. Impact of HPV sample self-collection for underscreened women in the renewed cervical screening program. Med J Aust. 2016;204(5):1941e–1947.PubMed
25.
Castle PE, de Sanjose S, Qiao YL, Belinson JL, Lazcano-Ponce E, Kinney W. Introduction of human papillomavirus DNA screening in the world: 15 years of experience. Vaccine. 2012;30(Suppl 5):F117–22.CrossRefPubMed
26.
27.
Joura EA, Giuliano AR, Iversen OE, Bouchard C, Mao C, Mehlsen J, Moreira ED Jr, Ngan Y, Petersen LK, Lazcano-Ponce E, et al. A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women. N Engl J Med. 2015;372(8):711–23.CrossRefPubMed
28.
Herrero R. Human papillomavirus (HPV) vaccines: limited cross-protection against additional HPV types. J Infect Dis. 2009;199(7):919–22.CrossRefPubMed
29.
Liu SS, Chan KY, Leung RC, Chan KK, Tam KF, Luk MH, Lo SS, Fong DY, Cheung AN, Lin ZQ, et al. Prevalence and risk factors of human papillomavirus (HPV) infection in southern Chinese women - a population-based study. PLoS One. 2011;6(5):e19244.CrossRefPubMedPubMedCentral
30.
Wu RF, Dai M, Qiao YL, Clifford GM, Liu ZH, Arslan A, Li N, Shi JF, Snijders PJ, Meijer CJ, et al. Human papillomavirus infection in women in Shenzhen City, People's Republic of China, a population typical of recent Chinese urbanisation. Int J Cancer. 2007;121(6):1306–11.CrossRefPubMed
31.
Chen Q, Luo ZY, Lin M, Lin QL, Chen CY, Yang C, Xie LX, Li H, Zheng JK, Yang LY, et al. Prevalence and genotype distribution of human papillomavirus infections in women attending hospitals in Chaozhou of Guangdong province. Asian Pac J Cancer Prev. 2012;13(4):1519–24.CrossRefPubMed
32.
Zeng XX, Yan LX, Huang XX, He CH, Liu WG, Yuan WQ, Qiu YP, Liu ZX. Prevalence and genotype distribution of human papillomavirus among Hakka women in China. Ann Transl Med. 2016;4(15):276.CrossRefPubMedPubMedCentral
33.
Kliucinskas M, Nadisauskiene RJ, Minkauskiene M. Prevalence and risk factors of HPV infection among high-risk rural and urban Lithuanian women. Gynecol Obstet Investig. 2006;62(3):173–80.CrossRef
34.
Jing L, Zhong X, Huang W, Liu Y, Wang M, Miao Z, Zhang X, Zou J, Zheng B, Chen C, et al. HPV genotypes and associated cervical cytological abnormalities in women from the Pearl River Delta region of Guangdong province, China: a cross-sectional study. BMC Infect Dis. 2014;14:388.CrossRefPubMedPubMedCentral
35.
Oakeshott P, Aghaizu A, Reid F, Howell-Jones R, Hay PE, Sadiq ST, Lacey CJ, Beddows S, Soldan K. Frequency and risk factors for prevalent, incident, and persistent genital carcinogenic human papillomavirus infection in sexually active women: community based cohort study. BMJ. 2012;344:e4168.CrossRefPubMedPubMedCentral
36.
Wang WZ, Wang CY, Cheng YT, Xu AL, Zhu CL, Wu SF, Kong QP, Zhang YP. tracing the origins of Hakka and Chaoshanese by mitochondrial DNA analysis. Am J Phys Anthropol. 2010;141(1):124–30.PubMed
37.
Zhu Y, Shennan M, Reynolds KK, Johnson NA, Herrnberger MR, Valdes R Jr, Linder MW. Estimation of warfarin maintenance dose based on VKORC1 (−1639 G>A) and CYP2C9 genotypes. Clin Chem. 2007;53(7):1199–205.CrossRefPubMed
Metadata
Title
Prevalence and genotype distribution of human papillomavirus infection among women in northeastern Guangdong Province of China
Authors
Pingsen Zhao
Sudong Liu
Zhixiong Zhong
Jingyuan Hou
Lifang Lin
Ruiqiang Weng
Luxian Su
Nanxiang Lei
Tao Hou
Haikun Yang
Publication date
01-12-2018
Publisher
BioMed Central
Published in
BMC Infectious Diseases / Issue 1/2018
Electronic ISSN: 1471-2334
DOI
https://doi.org/10.1186/s12879-018-3105-x

Other articles of this Issue 1/2018

BMC Infectious Diseases 1/2018 Go to the issue

Research article

Prevalence of glucose-6-phosphate dehydrogenase (G6PD) deficiency among malaria patients in Upper Myanmar

Research article

GeneChip analysis of resistant Mycobacterium tuberculosis with previously treated tuberculosis in Changchun

Research article

Molecular characterization of an outbreak of enterovirus-associated meningitis in Mossel Bay, South Africa, December 2015–January 2016

Research article

Identifying heterogeneity in the Hawthorne effect on hand hygiene observation: a cohort study of overtly and covertly observed results

Research article

Airborne geographical dispersal of Q fever from livestock holdings to human communities: a systematic review and critical appraisal of evidence

Research article

Acceptability of HIV self-testing to support pre-exposure prophylaxis among female sex workers in Uganda and Zambia: results from two randomized controlled trials
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits